Spyre logo: “Spyre” in navy capitalized text and “Therapeutics” in smaller navy capitalized text, deep pink “Y” antibody shape at the left

We are advancing a broad pipeline of potentially best-in-class antibodies. Learn more about the programs we are developing below.

STRATEGY
TARGET
PROGRAM
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3

Next-generation monotherapies Potential
SC Q8W-Q12W

α4β7
SPY001
PHASE 1

Our most advanced product candidate, SPY001, is designed to be a highly potent, selective, and half-life extended monoclonal antibody that binds to the α4β7 integrin.

TL1A
SPY002
PRECLINICAL

Our co-lead product candidate, SPY002, is designed to be a highly potent, selective, and half-life extended monoclonal antibody that binds to tumor necrosis factor-like ligand 1A (“TL1A”).

IL-23
SPY003
PRECLINICAL

Our co-lead product candidate, SPY003, is designed to be a highly potent, selective, and half-life extended monoclonal antibody that binds to the p19 subunit of interleukin-23 cytokine (“IL-23p19”).

Paradigm-changing combinationsPotential
SC Q8W-Q12W

α4β7 + TL1A
SPY120
PRECLINICAL
α4β7 + IL-23
SPY130
PRECLINICAL
TL1A + IL-23
SPY230
PRECLINICAL
OUR PUBLICATIONSOTHER REFERENCES